Thiogenesis Therapeutics received Rare Pediatric Disease designation from the FDA for its drug candidate TTI-0102, targeting Leigh syndrome, a serious mitochondrial disorder affecting children. This designation may allow the company to obtain a Priority Review Voucher upon drug approval, which can expedite future drug reviews or be sold. Thiogenesis plans to start a Phase 2 clinical trial soon, incorporating insights from previous studies to improve the treatment's effectiveness and safety. This milestone highlights the company's progress in addressing unmet medical needs in rare pediatric diseases.
Lands' End awarded CEO Charlie Cole inducement grants including 109,361 restricted stock units and options for 166,018 shares at $11.43 each, vesting over three years. These grants are outside shareholder-approved plans and aim to incentivize his lea...
Canon U.S.A. revealed its next-generation varioPRESS iV7 B2+ sheetfed inkjet press at the thINK Ahead 2026 conference, marking its first U.S. live demonstration. The varioPRESS iV7 offers high-speed printing up to 8,700 B2 sheets per hour, bridging t...
The U.S. Department of War has suspended the Cybersecurity Maturity Model Certification (CMMC) Phase II requirements originally set for November 2026, following concerns from small defense contractors about high compliance costs and bureaucratic burd...
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...
Silver Pony Resources Corp. has completed a 20-to-1 share consolidation and converted 21.25 million subscription receipts into units, each including a share and a warrant. The company also changed its name to Silver Pony Resources Corp. and awaits fi...
